(BFW) Merkel Ally Cites Doubts on Greek Aid, Tagesspiegel Says


BFW 06/11 13:21 Merkel Caucus May Refuse Greek Bailout Extension: Krichbaum
BN 06/11 13:17 *GERMAN CDU LAWMAKER KRICHBAUM CITED IN TAGESSPIEGEL INTERVIEW
BN 06/11 13:17 *KRICHBAUM DOESN'T SEE MAJORITY IN MERKEL CAUCUS: TAGESSPIEGEL
BFW 06/11 13:17 *MERKEL CAUCUS MAY REFUSE GREEK BAILOUT EXTENSION: KRICHBAUM

MORE: Merkel Ally Cites Doubts on Greek Aid, Tagesspiegel Says
2015-06-11 13:37:59.614 GMT


By Tony Czuczka
(Bloomberg) -- CDU’s Gunther Krichbaum says that, based on
the state of play in Greece talks, there would be no point for
Chancellor Angela Merkel to ask German lawmakers to vote for
extending the nation’s bailout, Tagesspiegel reports, citing
interview.

* Krichbaum has “serious doubts” that more than half of
Christian Democratic lawmakers would currently vote in
favor: Tagesspiegel
* NOTE: Merkel’s Christian Democratic Union-led bloc has 311
of 631 seats in lower house, or Bundestag; Merkel’s junior
coalition partner Social Democratic Party has 193.
* NOTE: SPD and opposition Greens have backed euro-area
bailouts in the past
* NOTE: Merkel’s Coalition Leaders Vent Frustration Over
Greece Impasse NSN NPONT16S972K<GO>


Earlier story: NSN NPS7RX6K50XV<GO>

For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>

To contact the reporter on this story:
Tony Czuczka in Berlin at +49-30-70010-6227 or
aczuczka@bloomberg.net
To contact the editors responsible for this story:
Alan Crawford at +49-30-70010-6237 or
acrawford6@bloomberg.net

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: BV -5.4%, GWR -0.6%, DEST -0.6%

M&A news: SYT -1% (cont uncertaintly surrounding merger with MON)

Select metals/mining stocks trading lower: MT -1.7%, AUY -1.5%, FCX -1%, SLV -1%, HMY -0.7%, GG -0.5%

Other news: FOLD -7.5% ( announces a $150 stock offering), COMM -5.9% ( announces sale of 20 mln shares of common stock by Carlyle Group), GLP -5.5% ( announces an offering of 3 mln common units), DRNA -5.5% (responds to complaint file by Alnylam Pharmaceuticals (ALNY) in US Superior Court; 'believes the complaint is meritless'), SALT -4.4% (prices offering of 133,000,000 shares of common stock at $1.50 per share), BBG -3.8% (announces "at-the-market" equity offering; confirms increase to 2015 capex budget; establishes initial 2016 production growth range), LULU -3.3% (discloses filing for sale of up to 20,109,131 shares by founder Dennis J. Wilson; if entire amount sold, it would represent Wilson's entire stake), FRSH -3.1% (announced secondary common stock offering of 2 mln shares by selling sharholder), CYBR -2.6% (prices offering of 4,900,000 ordinary shares at a price of $61.00 per share sold by co and selling shareholders), TUBE -2.5% (prices follow-on offering of 5,263,246 shares of common stock at a price to the public of $15.75 sold by co and selling shareholders), WNC -1.9% (amended credit agreement regarding its $150 million asset-based revolving credit facility), BAS -1.8% (filed for $1 bln mixed securities shelf offering), PFPT -1.5% (announced an offering of $150 mln in convertible senior notes due 2020), IEX -1.3% (acquired specialty products valve firm, Alfa Valvole, for €102 million; with earnings accretion expected in the first full year after closing), NLSN -1% (announces a secondary offering of ~8.95 mln shares of common stock by affiliates of the Blackstone Group and The Carlyle Group )

Analyst comments: CL -1.3% (downgraded to Equal-Weight from Overweight at Morgan Stanley), HOG -0.9% (downgraded to Neutral from Outperform at Wedbush), RIG -0.7% (initiated with an Underweight at Barclays), CHK -0.5% (downgraded to Perform from Outperform at Oppenheimer
)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: BOX +11.4%, MW +7.6%, KKD +6.2%, DDC +3.4%

M&A news: ISSI +3.6% (Integrated Silicon amends its merger agreement with Uphill Investment, increasing the acquisition price to $21/share from $20/share for ISSI shares), HE +0.6% (shareholders approve merger with NextEra Energy (NEE))

Other news: ATOS +10.7% (announces the U.S. Patent and Trademark Office has issued a new patent, Serial No. 9,052,318, to Atossa for Breast Cancer Detection using Absorbent Paper), ISIS +8% (reports Data from ISIS-SMN Rx Phase 2 Study in Infants with Spinal Muscular Atroph), CLLS +3.4% (announced publication of a study in Molecular Therapy describing the development of the next generation of engineered CAR T-cells compatible with allogeneic adoptive transfer immunotherapy), DMND +2.6% (favorable commentary on Wednesday's Mad Money), RBS +2.1% (UK confirms plans to begin sales of government's RBS stake - will begin in the coming months), AMGN +1.5% (FDA Advisory Committee votes 15-0 in favor of recommending approval of Repatha (evolocumab) for lowering LDL-C in patients with HoFH), AGIO +1.5% (confirms the FDA has granted it orphan drug designation for AG-120 for the treatment of patients with acute myelogenous leukemia), NKE +1.1% (NIKE to become exclusive oncourt provider for NBA, WNBA, NBA D-league), LNG +0.9% (announced 2 significant LNG projects; may add up to 19 mtpa in new liquefaction capacity by 2025), ISBC +0.7% (announced its second share repurchase program; may repurchase an additional 10% of its common stock, or ~34 mln shares)

Analyst comments: PTBI +13.2% (initiated with a Buy at ROTH Capital; tgt $16), AGEN +3.6% (initiated with an Outperform at Oppenheimer), NPTN +2.4% (upgraded to Outperform from Mkt Perform at Raymond James), RAD +2.2% (resumed with a Outperform at Credit Suisse), ERF +2.2% (upgraded to Buy from Hold at TD Securities), HZNP +1.9% (initiated with a Overweight at Morgan Stanley), TOL +1.7% (upgraded to Outperform from Neutral at Credit Suisse), FDX +1.2% (added to Focus List at Citigroup; target raised to $206 from $198 at Credit Suisse ), AWAY +0.8% (initiated with an Overweight at a boutique firm), HOS +0.7% (initiated with an Overweight at Barclays), NFLX +0.7% (target raised to $746 at Topeka Capital Markets), HLT +0.7% (initiated with a Buy at Brean Capital
)

>>> Elliott Management (7.1% holder) sends letter to Board; sees company reachin

Elliott Management (7.1% holder) sends letter to Board; sees company reaching $90-100+/shr by the end of 2016 if engages on a plan; suggests exploring options for GoTo and NetScaler 

We believe that Citrix can achieve a stock price of $90 $100+ per share by the end of 2016. This outcome which represents an increase in stockholder value of approximately 50% is achievable because Citrix has leading technology franchises in attractive markets but has struggled operationally for years. As a result, today Citrixs operations and product portfolio represent an opportunity for improvement of uniquely significant magnitude.

The purpose of todays letter is to a) introduce ourselves, b) preview some of the extensive work we have done to validate the $90 $100+ per share opportunity, and c) respectfully request a meeting with the Companys board of directors (the Board) to share our detailed thoughts about how to improve Citrix for the benefit of stockholders, employees and customers.

Spin or Sale of the GoTo Franchise: While we recognize the broad notion of empowering a mobile workforce, this businesss go-to-market strategy, product development roadmap and end-market are absolutely distinct from the core of Citrix. GoTo is an attractive business with scale in its market, and we have confidence that it can realize significant value through several alternative transaction structures, including a sale or a spin. We also further believe that core Citrixs management can create significantly more value for stockholders by focusing on operational execution rather than attempting to oversee the GoTo franchise.

Exploration of Strategic Alternatives for NetScaler: We are not explicitly advocating for a sale of NetScaler, but we believe the sale option should be seriously explored to assess potential strategic buyer interest and valuation, which we believe may be robust. NetScaler is an excellent business, and its ADC technology is an industry-leader; however, we believe Citrix has overly relied on the virtualization cross-sell, resulting in significant under-penetration in non-virtualization use-cases and within the telco vertical. We believe other strategic owners can accelerate NetScalers growth through greater scale and unique customer relationships. It is critical for the Board to consider whether Citrix is the parent company best positioned to maximize NetScalers value.

NYT : Why I’m Breaking Up With the Apple Watch

I wanted it to work. I wanted to fall in love, like so many of my friends. “It takes a while,” they said. “Don’t expect a coup de foudre. Let it build over time.”

So I did. I knew other people looked at what I had with envy. But a month and a half after we first got together, I have decided it is time to — well, call time.

I am breaking up with my Apple Watch. The relationship was, despite all expectations, not what I needed. All the focus on San Francisco and Apple’s next big innovation this week (streaming!) made me realize it was not playing my tune.

Still, I will never regret the weeks we spent together. They taught me some valuable truths about myself.

Like, for example, that I do not want to be defined by a talking point on my wrist.

There is a reason that I carry the same (no logo) handbag everywhere I go, a reason my (pre-Apple) watch had no bells or tourbillon whistles; a reason I gravitate toward clothes that are not identifiable by season or designer and do not appear in any advertisements I have ever seen.

I spend a lot of time in a world where products are shorthand for people, and I know too well the risks of having such semiology attached to myself (though I fully acknowledge my willingness to attach it to others).

But when I started wearing the Apple Watch (the 38-millimeter case with a Milanese Loop band, which is the smaller size with a flexible stainless steel bracelet), it became a subject of conversation no matter where I was: in meetings at work, at the bagel store, at my son’s track meet. It has been so everywhere, marketed to so many people, there was just no mistaking it.

First everyone wanted to know about it. Then they wanted to try it. Then they made certain assumptions about me.

Which, frankly, I would have made about any woman like myself walking around with a big black box on her arm.

Because no matter how attractive the Apple Watch is in the context of other smartwatches or smartbands, no matter how much of an aesthetic advance its rounded corners and rectangular display, it still looks like a gadget. Especially on someone, like me, with relatively small wrists.

Not only does its face effectively span the width of my forearm, but the cool little screen saver that so many reviewers have lauded — the Mickey or the butterfly or the galaxy (which is the one I have) or the pseudo-watch hands (the one that, notably, is always on in every picture of the watch, and actually makes it look like a watch) — is also functionally sleeping most of the time.

Every time I see it, I want to shriek, “Beam me up, Scotty.”

Not that it would do much good. Typing doesn’t awaken the picture. Even when I rock my arm back and forth energetically, it often takes a few tries before up the earth pops. The default position is blank.

Just as my default position when trying to read an email or the text of a headline on the small screen involves raising my wrist to near eye level — or, if a phone call is involved and my actual phone is not reachable, talking into thin air. If your children or acquaintances come upon you, it’s pretty much an invitation to ridicule.

Advertisement

Continue reading the main story
Advertisement

Continue reading the main story
Advertisement

Continue reading the main story
“Why is that more embarrassing than endlessly looking at a phone?” my friends said when I complained.

It’s a valid question, but after some contemplation I think the answer is simple: A phone is hand-held, and we are used to seeing people read things held in their hands. Like, say, books. But seeing somebody staring at her wrist (or merely sneaking a surreptitious glance at it) telegraphs something else entirely: (1) rudeness or (2) geekiness.

This doesn’t seem to have bothered the tech writers, most of whom wrote persuasively positive reviews of the gadget, primarily based on what it could do for you. And it is certainly more subtle than Google Glass, though I am not sure that is saying much.

Granted, all of this would likely pale in importance if the watch were truly transforming my life, as my iPhone has. But I have never had a problem turning away from my emails when I need to concentrate on something else — I’ve effectively trained myself to compartmentalize — so I need specific alerts as to what is important.

Continue reading the main story
RECENT COMMENTS

scratchbaker 6 hours ago
I don't even own a cellphone or smartphone. So I don't spend any time staring at a phone or showing other people photos they wish they...
Jesse T 6 hours ago
the author of this article is terribly honest.
grabbyg 6 hours ago
I love my apple watch. I love taking a call on it every now and then. I love looking at my wrist to see and answer messages. I love...
SEE ALL COMMENTS WRITE A COMMENT
And the small screen is simply too small to really read on, so I’ve been more annoyed than happy when it alerted me to texts from my loved ones; and when I saw a headline, all I wanted to do was find the rest of the story.

Besides, the busywork the watch’s apps can replace — handing over airline boarding passes, opening hotel room doors — seems less like an advance than a loss of control. Call me a Luddite, but honestly, I don’t mind unlocking things with my actual hands. The new watch OS announced this week may change the situation, but I am not sure I have the patience to wait.

Likewise (and I know this will be heresy to anyone really excited about the coming Fitbit initial public offering), the fitness-app aspect — the tracking of my steps, the measuring of my heart rate, the telling me to stand up when I am in the middle of an article — seems more like a burden than freedom.

I have worked hard to wean myself from a reliance on exercise machines telling me how hard I had worked — how many calories I had burned, how many stairs I had climbed — in part because I knew I was cheating pretty much all the time anyway and thus could not trust the results, and in part because it became an excuse to modify, or not, my ensuing behavior.

But the truth is, I know when I am in shape; I can see the difference in my body and feel it when I ride my bike in the park. The watch threatened to drag me back into a numbers-driven neurosis, and that’s a temptation I would rather not have. (Also, I have too many friends who look at their fitness tracker in the middle of conversation, then immediately spring up and start walking around energetically, to feel it is really additive to my life.)

I did like the fact that I could turn my phone ringer off, and the watch would vibrate when, say, my children were on the line and I needed to take the call. But in the end that wasn’t enough.

When I told a colleague about the breakup, he observed that perhaps I wasn’t the target for the Apple Watch. That I should be sure to tell the Siri on my wrist, “It’s not you, it’s me.” He may be right.

CONTINUE READING THE MAIN STORY
421
COMMENTS
Except I don’t think so, and not just because often, opposites do attract. But because I actually think I am the intended: a nontech person who wouldn’t otherwise have too many gadgets (a phone, an iPad, a laptop), but who could be seduced into buying another because of its desirability.

That’s the way Apple increases market share and owns a category, after all: by sucking in those who are not Apple addicts. It’s why the company worked so hard to get close to the fashion flock.

But here’s the thing: The watch isn’t actually a fashion accessory for the tech-happy. It’s a tech accessory pretending to be a fashion accessory. I just couldn’t fall for it.